{"": [162, 171, 0, 2267, 3084, 0, 3085, 4127, 0, 4128, 4770, 0], "Background": [172, 466, 0], "Methods": [467, 1043, 0], "Results": [1044, 1731, 0], "Conclusions": [1732, 2222, 0], "Clinical Trials Registration": [2223, 2266, 0], "Study Setting and Design": [4794, 5371, 0], "Study Participants": [5372, 5749, 0], "Data Collection": [5750, 6281, 0], "Polymerase Chain Reaction Measurement of SARS-CoV-2 Serum Antibody and Viral RNA": [6282, 6740, 0], "Follow-up Appointments": [6741, 7068, 0], "Study Outcomes": [7069, 7762, 0], "Surrogate Neutralization Assay": [7763, 8096, 0, 13450, 14364, 0], "MATERIALS AND METHODS": [4771, 8096, 1], "Participant Demographics": [8106, 9295, 0], "Factors Associated With Increased Peak Antibodies and Rapid Decay": [9296, 9664, 0], "Observed Antibody Kinetics and Seroreversion": [9665, 10766, 0], "Modeled Serological Reversion and Proportion of Positive Test Results Over Time": [10767, 12074, 0], "Antibody Peak, Half-Life, and Plateau": [12075, 13449, 0], "RESULTS": [8097, 14364, 1], "DISCUSSION": [14365, 23298, 0], "Supplementary Data": [23299, 23625, 0], "Supplementary Material": [23626, 23799, 0]}